Bascom Palmer Eye Institute

World's Most Influential People in Ophthalmology

Retrieved on: 
Giovedì, Maggio 9, 2024
Education, FDA, Bascom Palmer Eye Institute, Genetics, Teaching, Surgeon, Paratriathlon, Neuro-ophthalmology, Leach, Strabismus, Cataract, Knowledge, Bascom H. Palmer, Gedde, Eye, DRS, Retina, Vision science, Quality of life, Publication, Research, Bevacizumab, Artificial intelligence, Suture, Health, M.A, Choroideremia, Medeiros, Vance DeGeneres, University, Retinitis pigmentosa, Epidemiology, American Journal, Power, Patient, Physician, Uveitis, Glaucoma, Nursing

MIAMI, May 9, 2024 /PRNewswire/ -- Fifteen Bascom Palmer Eye Institute physicians were selected for the 2024 Power List, a prestigious selection of the world's 100 most influential people shaping the future of eye care, as published by The Ophthalmologist magazine. Drs. Eduardo C. Alfonso, Kendall Donaldson, Hilda Capó, Janet Davis, Harry Flynn, Anat Galor, Steven Gedde, Ranya Habash, Carol Karp, Jaclyn Kovach, Byron Lam, Felipe Medeiros, Richard Parrish, Philip Rosenfeld, and Sonia Yoo were named to the 2024 Power List. Bascom Palmer Eye Institute is the Department of Ophthalmology for the University of Miami Miller School of Medicine and UHealth – University of Miami Health System.

Key Points: 
  • Bascom Palmer Eye Institute is the Department of Ophthalmology for the University of Miami Miller School of Medicine and UHealth – University of Miami Health System.
  • From cutting-edge treatments to groundbreaking research, these doctors are pushing boundaries and setting new standards in ophthalmology."
  • Alfonso, the holder of the Kathleen and Stanley J. Glaser Chair in Ophthalmology, was also named to the Ophthalmologist Power Lists 2014, 2016, 2018, 2022, and 2023.
  • Holder of the John T. Flynn Chair in Ophthalmology, Hilda Capó, M.D., specializes in pediatric ophthalmology and adult strabismus.

Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result

Retrieved on: 
Mercoledì, Maggio 8, 2024
Research, Genetics, Clinical Trials, Biometrics, Biotechnology, General Health, Health, Optical, Science, Oncology, Bascom Palmer Eye Institute, University, Risk, MFS, PRAME, Glomus tumor, Patient, Eye, Metastasis, Uveal melanoma, Annual general meeting, ARVO, UM, Medical imaging

Further, the study provides prospective validation data supporting Preferentially Expressed Antigen in Melanoma (PRAME) as a risk refinement tool when considered in the context of a Class 1 or Class 2 DecisionDx-UM test result.

Key Points: 
  • Further, the study provides prospective validation data supporting Preferentially Expressed Antigen in Melanoma (PRAME) as a risk refinement tool when considered in the context of a Class 1 or Class 2 DecisionDx-UM test result.
  • The data was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle.
  • “The study data provides support for combining the reported expression status of the PRAME gene with the DecisionDx-UM class result to enhance metastatic risk prediction.
  • Patients with Class 2 tumors had considerably worse outcomes than those with Class 1 tumors, regardless of PRAME status; however, PRAME+ tumors fared worse within each GEP class (versus PRAME-).

Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium

Retrieved on: 
Mercoledì, Marzo 27, 2024
Opacity (optics), Risk, Patient, RBS, University, PDAT, Bascom Palmer Eye Institute, Rose bengal, Eye, Infection, Keratitis, Safety, Paratriathlon, Ophthalmology, OBC, Pharmaceutical industry

Provectus would contribute the license to the new entity and have an exclusive RBS supply arrangement with it.

Key Points: 
  • Provectus would contribute the license to the new entity and have an exclusive RBS supply arrangement with it.
  • Rose bengal PDAT emerged under the leadership of Jean-Marie Parel, IngETS-G, Ph.D., FARVO, Director of the Ophthalmic Biophysics Center (“OBC”) at Bascom Palmer Eye Institute (“BPEI”) at the University of Miami Miller School of Medicine.
  • The OBC team and Dr. Parel have spent many years advancing their PDAT technology using rose bengal against different types of treatment-naïve and -resistant keratitis.
  • Dr. Parel said, “Rose bengal PDAT is the result of a lot of hard work by cross-disciplinary contributors at the University of Miami.

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

Retrieved on: 
Giovedì, Marzo 21, 2024
Visual Science, Uveitis, Wilmer Ophthalmological Institute, Brandeis University, Neurophysiology, NCP, BID, Telecanthus, Research, KOL, University, Patient, Doctor of Philosophy, Bascom Palmer Eye Institute, DED, Georgetown University Medical Center, Pain, Therapy, Johns Hopkins Hospital, Medical director, FDA, Pharmaceutical industry

LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announces that it will be hosting a Key Opinion Leader (KOL) event on April 9th, 2024 at 12:00 PM ET to discuss in depth the findings of the new and comprehensive efficacy data readout from the Phase 2 trial of OK-101 in dry eye disease, which will be announced on March 22nd, 2024.

Key Points: 
  • OKYO Pharma’s management team will also be in attendance to present an overview of OK-101’s mechanism of action.
  • He has published over 200 peer-reviewed articles and has served on the editorial boards of several prestigious ophthalmology journals.
  • Additionally, statistically significant improvements were observed in both a “sign” (total conjunctival staining) and two “symptoms” (burning/stinging and blurred vision), which are FDA-recognized endpoints of dry eye disease.
  • The double-masked, randomized, placebo-controlled Phase 2 trial was conducted at six sites in the U.S. and enrolled 240 subjects with DED dosed twice-daily (BID).

Bruce Sherman, Chairman and Principal Owner of the Miami Marlins, to Receive 2024 Horatio Alger Award

Retrieved on: 
Martedì, Febbraio 6, 2024
Major League Baseball, American Dream, Sibling, Family, School, University, Research, PCM, Marlin, Southeastern United States, Dream, Queensborough Community College, Arthur Young, MBA, Crohn's disease, Acquisition, Trustee, Bascom Palmer Eye Institute, Miami Marlins, Sale, Education, Ulcerative colitis, Innovation, Student, Member, Medical school, Organization, Nursing

WASHINGTON, Feb. 6, 2024 /PRNewswire/ -- Horatio Alger Association of Distinguished Americans, Inc., a nonprofit educational organization honoring the achievements of outstanding individuals and encouraging youth to pursue their dreams through higher education, today announced that Bruce S. Sherman, chairman and principal owner of the Miami Marlins, has been selected for membership in this prestigious organization. Mr. Sherman joins 10 other exceptional business, civic and cultural leaders from across North America in receiving 2024 honors. For more than 75 years, the Horatio Alger Award has been annually bestowed upon esteemed individuals who have succeeded despite facing adversities, and who have remained committed to higher education and charitable efforts in their communities. 

Key Points: 
  • In 2017, he became the chairman and principal owner of the Miami Marlins, a Major League Baseball team.
  • "It is our utmost honor to present the Horatio Alger Award to these 11 outstanding leaders who have exemplified perseverance, passion and a deep appreciation for higher education," said James F. Dicke II, chairman, Horatio Alger Association and 2015 Horatio Alger Award recipient.
  • Mr. Sherman and the Member Class of 2024 will be formally inducted into the Association on April 4-6, 2024, during the Association's annual Horatio Alger Award Induction Ceremonies in Washington, D.C.
  • For more information about Horatio Alger Association and its Member Class of 2024, please visit www.horatioalger.org and follow the organization on Facebook , X , LinkedIn and Instagram .

OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board

Retrieved on: 
Mercoledì, Gennaio 31, 2024
Uveitis, Telecanthus, Research, University, Yale School of Medicine, Patient, Pain, Wilmer Ophthalmological Institute, Safety, FDA, NCP, Physician, DED, Eye, DRS, Bascom Palmer Eye Institute, Garden, Pharmaceutical industry

and Anat Galor, M.D., both from the Bascom Palmer Eye Institute, and Mark Milner, M.D., of the Goldman Eye in Palm Beach Gardens, Florida, have joined OKYO’s Scientific Advisory board.

Key Points: 
  • and Anat Galor, M.D., both from the Bascom Palmer Eye Institute, and Mark Milner, M.D., of the Goldman Eye in Palm Beach Gardens, Florida, have joined OKYO’s Scientific Advisory board.
  • Dr Victor Perez is a Director of Cornea Research at Bascom Palmer Eye Institute, at the University of Miami Miller School of Medicine.
  • He is a clinician-scientist investigator in the field of ocular immunology and ocular surface diseases and served as Director of Duke Eye Center’s Ocular Immunology Center before joining Bascom Palmer Eye Institute.
  • OKYO's Scientific Advisory Board now has an ideal blend of clinical expertise, including ocular surface disease and neuropathic corneal pain, from the leading experts in those fields."

New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)

Retrieved on: 
Giovedì, Febbraio 1, 2024
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Paratriathlon, Inflammation, Ranibizumab, Research, Ophthalmology, RVO, Patient, Diabetic retinopathy, Swelling, CRVO, BRVO, Food, ROG, Bascom Palmer Eye Institute, Retina, Blood, Macular edema, Angiogenesis, Roche, Eye, CST, Telescopic sight

In addition, patients in the studies maintained vision gains and robust retinal drying achieved in the first 24 weeks of the studies for more than one year.

Key Points: 
  • In addition, patients in the studies maintained vision gains and robust retinal drying achieved in the first 24 weeks of the studies for more than one year.
  • Retinal drying is an important clinical measure as swelling from excess fluid in the back of the eye has been associated with distorted and blurred vision.
  • In both studies, Vabysmo was well tolerated and the safety profile was consistent with previous studies.
  • “The sustained vision improvements and retinal drying seen up to 72 weeks reaffirm Vabysmo as an effective treatment for retinal vein occlusion,” said Ramin Tadayoni, M.D., Ph.D., head of ophthalmology at Université Paris Cité in Paris and president of EURETINA, who is presenting the data at Angiogenesis.

Ascidian Therapeutics Announces First-Ever IND for an RNA Exon Editor as FDA Approves Trial Plan and Fast Tracks ACDN-01 in Stargardt Disease and Other ABCA4 Retinopathies

Retrieved on: 
Lunedì, Gennaio 29, 2024
Retina, Patient, Therapy, DNA, Biotechnology, RNA, RNA editing, University, Stargardt disease, ABCA4, IND, Food, Interim, Safety, Fast Track, FDA, Bascom Palmer Eye Institute, Research, Pharmaceutical industry

BOSTON, Jan. 29, 2024 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company aspiring to treat human diseases by rewriting RNA, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application and granted Fast Track      designation for ACDN-01. ACDN-01 is the first-ever clinical-stage RNA exon editor and the only clinical-stage therapeutic targeting the genetic cause of Stargardt disease. Ascidian expects to initiate enrollment in the Phase 1/2 STELLAR study of ACDN-01 in Stargardt disease and other ABCA4 retinopathies in the first half of 2024.

Key Points: 
  • ACDN-01 is the first-ever clinical-stage RNA exon editor and the only clinical-stage therapeutic targeting the genetic cause of Stargardt disease.
  • Ascidian expects to initiate enrollment in the Phase 1/2 STELLAR study of ACDN-01 in Stargardt disease and other ABCA4 retinopathies in the first half of 2024.
  • Ascidian also announced that the FDA has granted Fast Track designation for ACDN-01.
  • This designation enables Ascidian to expedite development of ACDN-01 with regular feedback from FDA through the clinical-development process.

EyeCheq Bolsters its Executive Team Ahead of Launch

Retrieved on: 
Giovedì, Novembre 2, 2023
Risk, Bascom Palmer Eye Institute, EVP, Optometry, Stanford University, Health, Big data, Kaiser Permanente, MD, University of Cambridge, Eye, Bachelor, Growth, Quest Diagnostics, Paratriathlon, Quality, AI, CMO, Patient, Harvard University, Eye disease, Management, Medical device, Nursing, Ophthalmology

EyeCheq, an innovator in eye care with its autonomous eye screening platform, announces  Leadership Team expansion.

Key Points: 
  • EyeCheq, an innovator in eye care with its autonomous eye screening platform, announces  Leadership Team expansion.
  • Dr. Silva brings a wealth of expertise in ophthalmology and technological innovation to EyeCheq.
  • Dr. Ali Khoshnevis, EyeCheq CSO, noted "Dr. Silva's arrival promises to be a pivotal step in our journey towards groundbreaking healthcare solutions.
  • I am excited to join the EyeCheq leadership team and to have the opportunity to contribute to the company's growth focused on preventing eye disease and blindness."

Esteemed Ophthalmologist, Dr. Nicole J. Topilow, Joins OCLI Vision's Expert Team

Retrieved on: 
Martedì, Settembre 12, 2023
Columbia University, UC San Diego Health, Lake Success, Specialization, University, Internal medicine, University School, American Academy, American Academy of Ophthalmology, Research, Barnard College, Biology, Bascom Palmer Eye Institute, University of California, San Diego, Graves' ophthalmopathy, Achievement Medal, MD, Patient, New York University Grossman School of Medicine, Knowledge, Hospital, Textbook, Health, Dentistry, Nursing, Management, Mount Sinai West, Ophthalmology

GARDEN CITY, N.Y., Sept. 12, 2023 /PRNewswire-PRWeb/ -- OCLI Vision is proud to announce the addition of Dr. Nicole J. Topilow, MD, to their distinguished team of eye care specialists. Dr. Topilow is a highly skilled ophthalmologist with a specialization in ophthalmic plastic and reconstructive surgery. Her expertise and dedication to patient care make her a valuable asset to OCLI Vision, and she is set to commence her practice on September 18th, 2023.

Key Points: 
  • OCLI Vision proudly welcomes Dr. Nicole J. Topilow, a skilled ophthalmologist specializing in ophthalmic plastic and reconstructive surgery.
  • Dr. Topilow will be practicing across multiple OCLI Vision locations starting September 18th, 2023, offering her expertise to patients.
  • GARDEN CITY, N.Y., Sept. 12, 2023 /PRNewswire-PRWeb/ -- OCLI Vision is proud to announce the addition of Dr. Nicole J. Topilow, MD, to their distinguished team of eye care specialists.
  • "I couldn't be more excited to join OCLI Vision and support its mission to provide exceptional eye care to our community.